KOL Identification

A global healthcare investment firm wanted to perform a commercial due diligence (CDD) prior to investment in a company producing a novel handheld diagnostic.

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform

A leader in research tools and clinical diagnostic development asked us to evaluate the opportunity for an ultrasensitive detection platform in methylation analysis

A research tools start-up enlisted DeciBio to support their go-to-market strategy and activities for their novel sequencing technology by conducting pricing voice-of-customer research and evaluating potential pricing strategies

A major diagnostics manufacturer had developed a novel technology for the rapid detection of infectious pathogens and required assistance in developing commercialization strategy and sales tactics. DeciBio’s services were contracted to profile relevant stakeholders, characterize existing workflows and acquisition / implementation processes, and develop a product-specific launch strategy.

A multi-billion dollar life science company needed pre diligence on a potential acquisition target